RBC Capital Markets Rebalances UK SMID Portfolio, Adding Oxford BioMedica

Key Facts

1RBC Capital Markets replaced Dunelm Group PLC with Oxford BioMedica PLC in its UK small and mid-cap (SMID) portfolio.

2RBC set a price target of 1,170p for Oxford BioMedica, implying a potential total return of 94%.

3The portfolio change comes as the Iran conflict reshapes the global energy outlook.

RBC Capital Markets has announced a strategic rebalancing of its top ten UK small and mid-cap (SMID) stock picks. The investment bank replaced homewares retailer Dunelm Group PLC with biotech firm Oxford BioMedica PLC in its high-conviction portfolio. Analysts at RBC set an ambitious price target of 1,170p for Oxford BioMedica, suggesting a potential total return of approximately 94%. This adjustment reflects a shift in market strategy as the ongoing Iran conflict continues to reshape the global energy and geopolitical landscape. The removal of Dunelm Group comes as the bank pivots toward sectors with higher growth conviction and 'outperform' ratings. Investors are closely watching these portfolio shifts as indicators of institutional sentiment within the UK equity market during periods of heightened volatility.